nodes	percent_of_prediction	percent_of_DWPC	metapath
Rufinamide—SCN10A—skin cancer	0.558	1	CbGaD
Rufinamide—ALB—Vismodegib—skin cancer	0.0644	0.231	CbGbCtD
Rufinamide—ALB—Vemurafenib—skin cancer	0.0509	0.183	CbGbCtD
Rufinamide—CYP2E1—Dacarbazine—skin cancer	0.0404	0.145	CbGbCtD
Rufinamide—CYP3A4—Imiquimod—skin cancer	0.0291	0.105	CbGbCtD
Rufinamide—CYP3A4—Temozolomide—skin cancer	0.0291	0.105	CbGbCtD
Rufinamide—ALB—Fluorouracil—skin cancer	0.0229	0.0822	CbGbCtD
Rufinamide—CYP3A4—Vismodegib—skin cancer	0.0202	0.0725	CbGbCtD
Rufinamide—CYP3A4—Vemurafenib—skin cancer	0.016	0.0573	CbGbCtD
Rufinamide—CYP3A4—Docetaxel—skin cancer	0.00548	0.0197	CbGbCtD
Rufinamide—SCN7A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00344	0.0666	CbGpPWpGaD
Rufinamide—SCN11A—nerve—skin cancer	0.00329	0.152	CbGeAlD
Rufinamide—SCN11A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00307	0.0594	CbGpPWpGaD
Rufinamide—SCN8A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00281	0.0543	CbGpPWpGaD
Rufinamide—SCN8A—nerve—skin cancer	0.00249	0.115	CbGeAlD
Rufinamide—SCN9A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00227	0.0439	CbGpPWpGaD
Rufinamide—SCN3A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00217	0.042	CbGpPWpGaD
Rufinamide—SCN2A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00209	0.0404	CbGpPWpGaD
Rufinamide—SCN4A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00209	0.0404	CbGpPWpGaD
Rufinamide—SCN1A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00201	0.0389	CbGpPWpGaD
Rufinamide—CES1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00188	0.0363	CbGpPWpGaD
Rufinamide—SCN10A—nerve—skin cancer	0.00167	0.077	CbGeAlD
Rufinamide—SCN5A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00141	0.0274	CbGpPWpGaD
Rufinamide—SCN7A—L1CAM interactions—SCN10A—skin cancer	0.00132	0.0256	CbGpPWpGaD
Rufinamide—GRM5—female reproductive system—skin cancer	0.00126	0.0581	CbGeAlD
Rufinamide—SCN11A—L1CAM interactions—SCN10A—skin cancer	0.00118	0.0228	CbGpPWpGaD
Rufinamide—SCN8A—L1CAM interactions—SCN10A—skin cancer	0.00108	0.0208	CbGpPWpGaD
Rufinamide—GRM5—head—skin cancer	0.00105	0.0485	CbGeAlD
Rufinamide—CES1—neck—skin cancer	0.00098	0.0453	CbGeAlD
Rufinamide—SCN9A—L1CAM interactions—SCN10A—skin cancer	0.000871	0.0169	CbGpPWpGaD
Rufinamide—Back pain—Vismodegib—skin cancer	0.000866	0.0096	CcSEcCtD
Rufinamide—Nystagmus—Fluorouracil—skin cancer	0.000834	0.00925	CcSEcCtD
Rufinamide—SCN3A—L1CAM interactions—SCN10A—skin cancer	0.000833	0.0161	CbGpPWpGaD
Rufinamide—SCN4A—L1CAM interactions—SCN10A—skin cancer	0.0008	0.0155	CbGpPWpGaD
Rufinamide—SCN2A—L1CAM interactions—SCN10A—skin cancer	0.0008	0.0155	CbGpPWpGaD
Rufinamide—SCN7A—female reproductive system—skin cancer	0.000793	0.0367	CbGeAlD
Rufinamide—SCN11A—head—skin cancer	0.00078	0.036	CbGeAlD
Rufinamide—SCN1A—L1CAM interactions—SCN10A—skin cancer	0.000772	0.0149	CbGpPWpGaD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000757	0.0084	CcSEcCtD
Rufinamide—Disturbance in attention—Temozolomide—skin cancer	0.000746	0.00828	CcSEcCtD
Rufinamide—CES1—E2F transcription factor network—XRCC1—skin cancer	0.000723	0.014	CbGpPWpGaD
Rufinamide—Weight decreased—Vemurafenib—skin cancer	0.000718	0.00797	CcSEcCtD
Rufinamide—Nervous system disorder—Vismodegib—skin cancer	0.000716	0.00795	CcSEcCtD
Rufinamide—Skin disorder—Vismodegib—skin cancer	0.000709	0.00787	CcSEcCtD
Rufinamide—Breast disorder—Imiquimod—skin cancer	0.000708	0.00785	CcSEcCtD
Rufinamide—Infestation—Vemurafenib—skin cancer	0.000707	0.00785	CcSEcCtD
Rufinamide—Infestation NOS—Vemurafenib—skin cancer	0.000707	0.00785	CcSEcCtD
Rufinamide—CES1—connective tissue—skin cancer	0.000702	0.0325	CbGeAlD
Rufinamide—Influenza—Imiquimod—skin cancer	0.000677	0.00751	CcSEcCtD
Rufinamide—SCN7A—head—skin cancer	0.000663	0.0306	CbGeAlD
Rufinamide—Gait disturbance—Temozolomide—skin cancer	0.000662	0.00735	CcSEcCtD
Rufinamide—CES1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000661	0.0128	CbGpPWpGaD
Rufinamide—Coordination abnormal—Temozolomide—skin cancer	0.000658	0.0073	CcSEcCtD
Rufinamide—Bronchitis—Imiquimod—skin cancer	0.000651	0.00722	CcSEcCtD
Rufinamide—Dyspepsia—Vismodegib—skin cancer	0.000643	0.00713	CcSEcCtD
Rufinamide—Decreased appetite—Vismodegib—skin cancer	0.000635	0.00704	CcSEcCtD
Rufinamide—Dysuria—Imiquimod—skin cancer	0.000633	0.00702	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Vismodegib—skin cancer	0.000631	0.007	CcSEcCtD
Rufinamide—Fatigue—Vismodegib—skin cancer	0.00063	0.00699	CcSEcCtD
Rufinamide—Constipation—Vismodegib—skin cancer	0.000625	0.00693	CcSEcCtD
Rufinamide—Urinary incontinence—Temozolomide—skin cancer	0.000624	0.00693	CcSEcCtD
Rufinamide—Infestation NOS—Imiquimod—skin cancer	0.000603	0.00669	CcSEcCtD
Rufinamide—Infestation—Imiquimod—skin cancer	0.000603	0.00669	CcSEcCtD
Rufinamide—Eye disorder—Vemurafenib—skin cancer	0.000594	0.00659	CcSEcCtD
Rufinamide—SCN8A—head—skin cancer	0.000591	0.0273	CbGeAlD
Rufinamide—Cardiac disorder—Vemurafenib—skin cancer	0.000589	0.00654	CcSEcCtD
Rufinamide—Mediastinal disorder—Vemurafenib—skin cancer	0.000572	0.00635	CcSEcCtD
Rufinamide—Hepatobiliary disease—Imiquimod—skin cancer	0.000571	0.00633	CcSEcCtD
Rufinamide—Sinusitis—Imiquimod—skin cancer	0.000566	0.00628	CcSEcCtD
Rufinamide—Malnutrition—Vemurafenib—skin cancer	0.000553	0.00613	CcSEcCtD
Rufinamide—Rhinitis—Imiquimod—skin cancer	0.000543	0.00602	CcSEcCtD
Rufinamide—SCN5A—L1CAM interactions—SCN10A—skin cancer	0.000543	0.0105	CbGpPWpGaD
Rufinamide—Urinary tract disorder—Imiquimod—skin cancer	0.000535	0.00593	CcSEcCtD
Rufinamide—Back pain—Vemurafenib—skin cancer	0.000535	0.00593	CcSEcCtD
Rufinamide—Urethral disorder—Imiquimod—skin cancer	0.000531	0.00589	CcSEcCtD
Rufinamide—Asthenia—Vismodegib—skin cancer	0.000524	0.00581	CcSEcCtD
Rufinamide—Pruritus—Vismodegib—skin cancer	0.000517	0.00573	CcSEcCtD
Rufinamide—CES1—lymphoid tissue—skin cancer	0.000513	0.0237	CbGeAlD
Rufinamide—Eye disorder—Imiquimod—skin cancer	0.000506	0.00562	CcSEcCtD
Rufinamide—Diarrhoea—Vismodegib—skin cancer	0.0005	0.00554	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—SCN10A—skin cancer	0.000499	0.00967	CbGpPWpGaD
Rufinamide—CES1—female reproductive system—skin cancer	0.000495	0.0229	CbGeAlD
Rufinamide—GRM5—GPCR ligand binding—PTCH2—skin cancer	0.000492	0.00952	CbGpPWpGaD
Rufinamide—SCN10A—lymphoid tissue—skin cancer	0.000491	0.0227	CbGeAlD
Rufinamide—Immune system disorder—Imiquimod—skin cancer	0.000489	0.00543	CcSEcCtD
Rufinamide—Mediastinal disorder—Imiquimod—skin cancer	0.000488	0.00542	CcSEcCtD
Rufinamide—Bone disorder—Docetaxel—skin cancer	0.000476	0.00528	CcSEcCtD
Rufinamide—Mental disorder—Imiquimod—skin cancer	0.000475	0.00527	CcSEcCtD
Rufinamide—Malnutrition—Imiquimod—skin cancer	0.000471	0.00523	CcSEcCtD
Rufinamide—Diplopia—Temozolomide—skin cancer	0.000469	0.00521	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000467	0.00519	CcSEcCtD
Rufinamide—Vomiting—Vismodegib—skin cancer	0.000464	0.00515	CcSEcCtD
Rufinamide—SCN7A—lymph node—skin cancer	0.000464	0.0215	CbGeAlD
Rufinamide—SCN4A—head—skin cancer	0.000463	0.0214	CbGeAlD
Rufinamide—Rash—Vismodegib—skin cancer	0.000461	0.00511	CcSEcCtD
Rufinamide—Dermatitis—Vismodegib—skin cancer	0.00046	0.0051	CcSEcCtD
Rufinamide—Back pain—Imiquimod—skin cancer	0.000456	0.00506	CcSEcCtD
Rufinamide—Infection—Vemurafenib—skin cancer	0.000448	0.00497	CcSEcCtD
Rufinamide—SCN1A—head—skin cancer	0.000447	0.0206	CbGeAlD
Rufinamide—SCN11A—Axon guidance—SCN10A—skin cancer	0.000445	0.00861	CbGpPWpGaD
Rufinamide—Nervous system disorder—Vemurafenib—skin cancer	0.000442	0.00491	CcSEcCtD
Rufinamide—Ataxia—Temozolomide—skin cancer	0.000441	0.0049	CcSEcCtD
Rufinamide—Skin disorder—Vemurafenib—skin cancer	0.000438	0.00486	CcSEcCtD
Rufinamide—Weight decreased—Bleomycin—skin cancer	0.000435	0.00483	CcSEcCtD
Rufinamide—Nausea—Vismodegib—skin cancer	0.000434	0.00481	CcSEcCtD
Rufinamide—Agitation—Imiquimod—skin cancer	0.000433	0.00481	CcSEcCtD
Rufinamide—SCN3A—female reproductive system—skin cancer	0.000431	0.0199	CbGeAlD
Rufinamide—Pneumonia—Bleomycin—skin cancer	0.000431	0.00478	CcSEcCtD
Rufinamide—Breast disorder—Temozolomide—skin cancer	0.000424	0.0047	CcSEcCtD
Rufinamide—Neutropenia—Dactinomycin—skin cancer	0.000419	0.00465	CcSEcCtD
Rufinamide—CES1—head—skin cancer	0.000414	0.0191	CbGeAlD
Rufinamide—SCN2A—head—skin cancer	0.00041	0.019	CbGeAlD
Rufinamide—Haematuria—Bleomycin—skin cancer	0.000409	0.00453	CcSEcCtD
Rufinamide—Convulsion—Imiquimod—skin cancer	0.000409	0.00453	CcSEcCtD
Rufinamide—SCN8A—Axon guidance—SCN10A—skin cancer	0.000407	0.00788	CbGpPWpGaD
Rufinamide—Ataxia—Fluorouracil—skin cancer	0.000406	0.00451	CcSEcCtD
Rufinamide—Pneumonia—Dactinomycin—skin cancer	0.000402	0.00446	CcSEcCtD
Rufinamide—Anxiety—Imiquimod—skin cancer	0.0004	0.00444	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000399	0.00442	CcSEcCtD
Rufinamide—SCN10A—head—skin cancer	0.000395	0.0183	CbGeAlD
Rufinamide—Decreased appetite—Vemurafenib—skin cancer	0.000392	0.00435	CcSEcCtD
Rufinamide—Bronchitis—Temozolomide—skin cancer	0.00039	0.00433	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00039	0.00432	CcSEcCtD
Rufinamide—Fatigue—Vemurafenib—skin cancer	0.000389	0.00432	CcSEcCtD
Rufinamide—Nasopharyngitis—Fluorouracil—skin cancer	0.000387	0.00429	CcSEcCtD
Rufinamide—Constipation—Vemurafenib—skin cancer	0.000386	0.00428	CcSEcCtD
Rufinamide—Infection—Imiquimod—skin cancer	0.000382	0.00424	CcSEcCtD
Rufinamide—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000382	0.0074	CbGpPWpGaD
Rufinamide—Neutropenia—Temozolomide—skin cancer	0.000379	0.00421	CcSEcCtD
Rufinamide—Dysuria—Temozolomide—skin cancer	0.000379	0.00421	CcSEcCtD
Rufinamide—Nervous system disorder—Imiquimod—skin cancer	0.000377	0.00419	CcSEcCtD
Rufinamide—Pollakiuria—Temozolomide—skin cancer	0.000375	0.00416	CcSEcCtD
Rufinamide—Skin disorder—Imiquimod—skin cancer	0.000374	0.00415	CcSEcCtD
Rufinamide—Weight decreased—Temozolomide—skin cancer	0.000367	0.00407	CcSEcCtD
Rufinamide—Anorexia—Imiquimod—skin cancer	0.000367	0.00407	CcSEcCtD
Rufinamide—Pneumonia—Temozolomide—skin cancer	0.000364	0.00404	CcSEcCtD
Rufinamide—SCN9A—lymph node—skin cancer	0.000364	0.0168	CbGeAlD
Rufinamide—Infestation NOS—Temozolomide—skin cancer	0.000362	0.00401	CcSEcCtD
Rufinamide—Infestation—Temozolomide—skin cancer	0.000362	0.00401	CcSEcCtD
Rufinamide—SCN3A—head—skin cancer	0.00036	0.0167	CbGeAlD
Rufinamide—SCN5A—head—skin cancer	0.000359	0.0166	CbGeAlD
Rufinamide—SCN7A—Developmental Biology—SCN10A—skin cancer	0.000356	0.0069	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—MC1R—skin cancer	0.000356	0.00689	CbGpPWpGaD
Rufinamide—Insomnia—Imiquimod—skin cancer	0.000348	0.00386	CcSEcCtD
Rufinamide—Somnolence—Imiquimod—skin cancer	0.000342	0.0038	CcSEcCtD
Rufinamide—Hepatobiliary disease—Temozolomide—skin cancer	0.000342	0.00379	CcSEcCtD
Rufinamide—Sinusitis—Temozolomide—skin cancer	0.000339	0.00376	CcSEcCtD
Rufinamide—Dyspepsia—Imiquimod—skin cancer	0.000339	0.00376	CcSEcCtD
Rufinamide—Pneumonia—Fluorouracil—skin cancer	0.000335	0.00372	CcSEcCtD
Rufinamide—Decreased appetite—Imiquimod—skin cancer	0.000335	0.00371	CcSEcCtD
Rufinamide—Infestation NOS—Fluorouracil—skin cancer	0.000333	0.0037	CcSEcCtD
Rufinamide—Infestation—Fluorouracil—skin cancer	0.000333	0.0037	CcSEcCtD
Rufinamide—Hypersensitivity—Vemurafenib—skin cancer	0.000332	0.00369	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000332	0.00369	CcSEcCtD
Rufinamide—Fatigue—Imiquimod—skin cancer	0.000332	0.00368	CcSEcCtD
Rufinamide—SCN9A—Axon guidance—SCN10A—skin cancer	0.000329	0.00637	CbGpPWpGaD
Rufinamide—Asthenia—Vemurafenib—skin cancer	0.000324	0.00359	CcSEcCtD
Rufinamide—Urinary tract disorder—Temozolomide—skin cancer	0.000321	0.00356	CcSEcCtD
Rufinamide—Pruritus—Vemurafenib—skin cancer	0.000319	0.00354	CcSEcCtD
Rufinamide—Urethral disorder—Temozolomide—skin cancer	0.000318	0.00353	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—SCN10A—skin cancer	0.000318	0.00615	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—SCN10A—skin cancer	0.000315	0.0061	CbGpPWpGaD
Rufinamide—Epistaxis—Fluorouracil—skin cancer	0.000314	0.00349	CcSEcCtD
Rufinamide—Sinusitis—Fluorouracil—skin cancer	0.000313	0.00347	CcSEcCtD
Rufinamide—Anaemia—Bleomycin—skin cancer	0.00031	0.00344	CcSEcCtD
Rufinamide—Diarrhoea—Vemurafenib—skin cancer	0.000309	0.00343	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—RHOU—skin cancer	0.000305	0.00591	CbGpPWpGaD
Rufinamide—Eye disorder—Temozolomide—skin cancer	0.000303	0.00337	CcSEcCtD
Rufinamide—SCN2A—Axon guidance—SCN10A—skin cancer	0.000302	0.00586	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—SCN10A—skin cancer	0.000302	0.00586	CbGpPWpGaD
Rufinamide—Cardiac disorder—Temozolomide—skin cancer	0.000301	0.00334	CcSEcCtD
Rufinamide—Leukopenia—Bleomycin—skin cancer	0.0003	0.00333	CcSEcCtD
Rufinamide—Rhinitis—Fluorouracil—skin cancer	0.0003	0.00333	CcSEcCtD
Rufinamide—Dizziness—Vemurafenib—skin cancer	0.000298	0.00331	CcSEcCtD
Rufinamide—Ataxia—Docetaxel—skin cancer	0.000293	0.00326	CcSEcCtD
Rufinamide—Immune system disorder—Temozolomide—skin cancer	0.000293	0.00325	CcSEcCtD
Rufinamide—Mediastinal disorder—Temozolomide—skin cancer	0.000293	0.00325	CcSEcCtD
Rufinamide—SCN1A—Axon guidance—SCN10A—skin cancer	0.000292	0.00565	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—SCN10A—skin cancer	0.00029	0.00562	CbGpPWpGaD
Rufinamide—CES1—lymph node—skin cancer	0.00029	0.0134	CbGeAlD
Rufinamide—Anaemia—Dactinomycin—skin cancer	0.000289	0.0032	CcSEcCtD
Rufinamide—Vomiting—Vemurafenib—skin cancer	0.000287	0.00318	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—RASA1—skin cancer	0.000287	0.00555	CbGpPWpGaD
Rufinamide—Abdominal pain upper—Docetaxel—skin cancer	0.000285	0.00316	CcSEcCtD
Rufinamide—Rash—Vemurafenib—skin cancer	0.000284	0.00316	CcSEcCtD
Rufinamide—Mental disorder—Temozolomide—skin cancer	0.000284	0.00316	CcSEcCtD
Rufinamide—Dermatitis—Vemurafenib—skin cancer	0.000284	0.00315	CcSEcCtD
Rufinamide—Hypersensitivity—Imiquimod—skin cancer	0.000284	0.00315	CcSEcCtD
Rufinamide—Headache—Vemurafenib—skin cancer	0.000283	0.00314	CcSEcCtD
Rufinamide—Malnutrition—Temozolomide—skin cancer	0.000283	0.00314	CcSEcCtD
Rufinamide—Breast disorder—Docetaxel—skin cancer	0.000282	0.00313	CcSEcCtD
Rufinamide—Leukopenia—Dactinomycin—skin cancer	0.00028	0.0031	CcSEcCtD
Rufinamide—Nasopharyngitis—Docetaxel—skin cancer	0.000279	0.0031	CcSEcCtD
Rufinamide—SCN10A—lymph node—skin cancer	0.000277	0.0128	CbGeAlD
Rufinamide—Asthenia—Imiquimod—skin cancer	0.000276	0.00306	CcSEcCtD
Rufinamide—Back pain—Temozolomide—skin cancer	0.000273	0.00303	CcSEcCtD
Rufinamide—Pruritus—Imiquimod—skin cancer	0.000272	0.00302	CcSEcCtD
Rufinamide—Infection—Bleomycin—skin cancer	0.000272	0.00301	CcSEcCtD
Rufinamide—Nausea—Vemurafenib—skin cancer	0.000268	0.00297	CcSEcCtD
Rufinamide—Thrombocytopenia—Bleomycin—skin cancer	0.000268	0.00297	CcSEcCtD
Rufinamide—Vision blurred—Temozolomide—skin cancer	0.000266	0.00295	CcSEcCtD
Rufinamide—Tremor—Temozolomide—skin cancer	0.000265	0.00294	CcSEcCtD
Rufinamide—Diarrhoea—Imiquimod—skin cancer	0.000263	0.00292	CcSEcCtD
Rufinamide—Anaemia—Temozolomide—skin cancer	0.000261	0.0029	CcSEcCtD
Rufinamide—Anorexia—Bleomycin—skin cancer	0.000261	0.00289	CcSEcCtD
Rufinamide—Agitation—Temozolomide—skin cancer	0.00026	0.00288	CcSEcCtD
Rufinamide—SCN11A—Axon guidance—RASA1—skin cancer	0.000256	0.00495	CbGpPWpGaD
Rufinamide—Dizziness—Imiquimod—skin cancer	0.000254	0.00282	CcSEcCtD
Rufinamide—Vertigo—Temozolomide—skin cancer	0.000254	0.00282	CcSEcCtD
Rufinamide—GRM5—GPCR ligand binding—SHH—skin cancer	0.000253	0.00491	CbGpPWpGaD
Rufinamide—Infection—Dactinomycin—skin cancer	0.000253	0.00281	CcSEcCtD
Rufinamide—Leukopenia—Temozolomide—skin cancer	0.000253	0.00281	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—PTCH2—skin cancer	0.000252	0.00489	CbGpPWpGaD
Rufinamide—SCN3A—lymph node—skin cancer	0.000252	0.0117	CbGeAlD
Rufinamide—Neutropenia—Docetaxel—skin cancer	0.000252	0.0028	CcSEcCtD
Rufinamide—Thrombocytopenia—Dactinomycin—skin cancer	0.00025	0.00277	CcSEcCtD
Rufinamide—Vision blurred—Fluorouracil—skin cancer	0.000245	0.00272	CcSEcCtD
Rufinamide—Convulsion—Temozolomide—skin cancer	0.000245	0.00272	CcSEcCtD
Rufinamide—Vomiting—Imiquimod—skin cancer	0.000245	0.00271	CcSEcCtD
Rufinamide—Weight decreased—Docetaxel—skin cancer	0.000244	0.00271	CcSEcCtD
Rufinamide—Anorexia—Dactinomycin—skin cancer	0.000243	0.0027	CcSEcCtD
Rufinamide—Rash—Imiquimod—skin cancer	0.000243	0.00269	CcSEcCtD
Rufinamide—Dermatitis—Imiquimod—skin cancer	0.000242	0.00269	CcSEcCtD
Rufinamide—Pneumonia—Docetaxel—skin cancer	0.000242	0.00268	CcSEcCtD
Rufinamide—Headache—Imiquimod—skin cancer	0.000241	0.00267	CcSEcCtD
Rufinamide—Anaemia—Fluorouracil—skin cancer	0.000241	0.00267	CcSEcCtD
Rufinamide—Infestation NOS—Docetaxel—skin cancer	0.00024	0.00267	CcSEcCtD
Rufinamide—Infestation—Docetaxel—skin cancer	0.00024	0.00267	CcSEcCtD
Rufinamide—GRM5—GPCR ligand binding—PTCH1—skin cancer	0.00024	0.00465	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—SMO—skin cancer	0.00024	0.00465	CbGpPWpGaD
Rufinamide—Anxiety—Temozolomide—skin cancer	0.00024	0.00266	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000239	0.00265	CcSEcCtD
Rufinamide—Decreased appetite—Bleomycin—skin cancer	0.000238	0.00264	CcSEcCtD
Rufinamide—CES1—Fluoropyrimidine Activity—TP53—skin cancer	0.000236	0.00456	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—SCN10A—skin cancer	0.000235	0.00455	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—PTGER4—skin cancer	0.000234	0.00453	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—RASA1—skin cancer	0.000234	0.00453	CbGpPWpGaD
Rufinamide—Leukopenia—Fluorouracil—skin cancer	0.000233	0.00259	CcSEcCtD
Rufinamide—Infection—Temozolomide—skin cancer	0.000229	0.00254	CcSEcCtD
Rufinamide—Nausea—Imiquimod—skin cancer	0.000229	0.00254	CcSEcCtD
Rufinamide—Hepatobiliary disease—Docetaxel—skin cancer	0.000227	0.00252	CcSEcCtD
Rufinamide—Epistaxis—Docetaxel—skin cancer	0.000227	0.00252	CcSEcCtD
Rufinamide—Nervous system disorder—Temozolomide—skin cancer	0.000226	0.00251	CcSEcCtD
Rufinamide—Thrombocytopenia—Temozolomide—skin cancer	0.000226	0.00251	CcSEcCtD
Rufinamide—Convulsion—Fluorouracil—skin cancer	0.000226	0.0025	CcSEcCtD
Rufinamide—SCN3A—Developmental Biology—SCN10A—skin cancer	0.000225	0.00435	CbGpPWpGaD
Rufinamide—CES1—E2F transcription factor network—CDKN2A—skin cancer	0.000224	0.00435	CbGpPWpGaD
Rufinamide—Skin disorder—Temozolomide—skin cancer	0.000224	0.00249	CcSEcCtD
Rufinamide—Decreased appetite—Dactinomycin—skin cancer	0.000222	0.00246	CcSEcCtD
Rufinamide—Fatigue—Dactinomycin—skin cancer	0.00022	0.00244	CcSEcCtD
Rufinamide—Anorexia—Temozolomide—skin cancer	0.00022	0.00244	CcSEcCtD
Rufinamide—Rhinitis—Docetaxel—skin cancer	0.000216	0.0024	CcSEcCtD
Rufinamide—SCN2A—Developmental Biology—SCN10A—skin cancer	0.000216	0.00418	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—SCN10A—skin cancer	0.000216	0.00418	CbGpPWpGaD
Rufinamide—Urinary tract disorder—Docetaxel—skin cancer	0.000213	0.00237	CcSEcCtD
Rufinamide—Urethral disorder—Docetaxel—skin cancer	0.000212	0.00235	CcSEcCtD
Rufinamide—CYP2E1—lymphoid tissue—skin cancer	0.000211	0.00976	CbGeAlD
Rufinamide—Infection—Fluorouracil—skin cancer	0.000211	0.00234	CcSEcCtD
Rufinamide—Insomnia—Temozolomide—skin cancer	0.000209	0.00231	CcSEcCtD
Rufinamide—Nervous system disorder—Fluorouracil—skin cancer	0.000208	0.00231	CcSEcCtD
Rufinamide—SCN1A—Developmental Biology—SCN10A—skin cancer	0.000208	0.00403	CbGpPWpGaD
Rufinamide—Thrombocytopenia—Fluorouracil—skin cancer	0.000208	0.00231	CcSEcCtD
Rufinamide—SCN5A—Axon guidance—SCN10A—skin cancer	0.000205	0.00397	CbGpPWpGaD
Rufinamide—Somnolence—Temozolomide—skin cancer	0.000205	0.00227	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—RASA1—skin cancer	0.000205	0.00396	CbGpPWpGaD
Rufinamide—CYP2E1—female reproductive system—skin cancer	0.000204	0.00941	CbGeAlD
Rufinamide—Dyspepsia—Temozolomide—skin cancer	0.000203	0.00225	CcSEcCtD
Rufinamide—Anorexia—Fluorouracil—skin cancer	0.000203	0.00225	CcSEcCtD
Rufinamide—Eye disorder—Docetaxel—skin cancer	0.000202	0.00224	CcSEcCtD
Rufinamide—Hypersensitivity—Bleomycin—skin cancer	0.000201	0.00223	CcSEcCtD
Rufinamide—ALB—lymph node—skin cancer	0.000201	0.00931	CbGeAlD
Rufinamide—GRM5—GPCR downstream signaling—MC1R—skin cancer	0.000201	0.00389	CbGpPWpGaD
Rufinamide—Decreased appetite—Temozolomide—skin cancer	0.0002	0.00222	CcSEcCtD
Rufinamide—Cardiac disorder—Docetaxel—skin cancer	0.0002	0.00222	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000199	0.00221	CcSEcCtD
Rufinamide—Fatigue—Temozolomide—skin cancer	0.000199	0.00221	CcSEcCtD
Rufinamide—Constipation—Temozolomide—skin cancer	0.000197	0.00219	CcSEcCtD
Rufinamide—Asthenia—Bleomycin—skin cancer	0.000196	0.00218	CcSEcCtD
Rufinamide—Immune system disorder—Docetaxel—skin cancer	0.000195	0.00216	CcSEcCtD
Rufinamide—Mediastinal disorder—Docetaxel—skin cancer	0.000195	0.00216	CcSEcCtD
Rufinamide—Pruritus—Bleomycin—skin cancer	0.000193	0.00215	CcSEcCtD
Rufinamide—Insomnia—Fluorouracil—skin cancer	0.000192	0.00213	CcSEcCtD
Rufinamide—Mental disorder—Docetaxel—skin cancer	0.000189	0.0021	CcSEcCtD
Rufinamide—SCN9A—Axon guidance—RASA1—skin cancer	0.000189	0.00366	CbGpPWpGaD
Rufinamide—Somnolence—Fluorouracil—skin cancer	0.000189	0.0021	CcSEcCtD
Rufinamide—Malnutrition—Docetaxel—skin cancer	0.000188	0.00208	CcSEcCtD
Rufinamide—Hypersensitivity—Dactinomycin—skin cancer	0.000188	0.00208	CcSEcCtD
Rufinamide—Dyspepsia—Fluorouracil—skin cancer	0.000187	0.00208	CcSEcCtD
Rufinamide—Decreased appetite—Fluorouracil—skin cancer	0.000185	0.00205	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000183	0.00204	CcSEcCtD
Rufinamide—Asthenia—Dactinomycin—skin cancer	0.000183	0.00203	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—MC1R—skin cancer	0.000183	0.00353	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—RASA1—skin cancer	0.000182	0.00353	CbGpPWpGaD
Rufinamide—Back pain—Docetaxel—skin cancer	0.000182	0.00202	CcSEcCtD
Rufinamide—SCN3A—Axon guidance—RASA1—skin cancer	0.000181	0.0035	CbGpPWpGaD
Rufinamide—Diarrhoea—Dactinomycin—skin cancer	0.000174	0.00194	CcSEcCtD
Rufinamide—Vomiting—Bleomycin—skin cancer	0.000174	0.00193	CcSEcCtD
Rufinamide—SCN2A—Axon guidance—RASA1—skin cancer	0.000174	0.00336	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—RASA1—skin cancer	0.000174	0.00336	CbGpPWpGaD
Rufinamide—Anaemia—Docetaxel—skin cancer	0.000174	0.00193	CcSEcCtD
Rufinamide—Rash—Bleomycin—skin cancer	0.000172	0.00191	CcSEcCtD
Rufinamide—Dermatitis—Bleomycin—skin cancer	0.000172	0.00191	CcSEcCtD
Rufinamide—CYP2E1—head—skin cancer	0.00017	0.00786	CbGeAlD
Rufinamide—Hypersensitivity—Temozolomide—skin cancer	0.00017	0.00189	CcSEcCtD
Rufinamide—Leukopenia—Docetaxel—skin cancer	0.000168	0.00187	CcSEcCtD
Rufinamide—SCN1A—Axon guidance—RASA1—skin cancer	0.000168	0.00324	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—RASA1—skin cancer	0.000168	0.00324	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—RASA1—skin cancer	0.000167	0.00323	CbGpPWpGaD
Rufinamide—Asthenia—Temozolomide—skin cancer	0.000165	0.00184	CcSEcCtD
Rufinamide—CYP3A4—female reproductive system—skin cancer	0.000164	0.00757	CbGeAlD
Rufinamide—Pruritus—Temozolomide—skin cancer	0.000163	0.00181	CcSEcCtD
Rufinamide—Convulsion—Docetaxel—skin cancer	0.000163	0.00181	CcSEcCtD
Rufinamide—Nausea—Bleomycin—skin cancer	0.000162	0.0018	CcSEcCtD
Rufinamide—Vomiting—Dactinomycin—skin cancer	0.000162	0.0018	CcSEcCtD
Rufinamide—Rash—Dactinomycin—skin cancer	0.000161	0.00178	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000159	0.00176	CcSEcCtD
Rufinamide—Diarrhoea—Temozolomide—skin cancer	0.000158	0.00175	CcSEcCtD
Rufinamide—Hypersensitivity—Fluorouracil—skin cancer	0.000157	0.00174	CcSEcCtD
Rufinamide—Dizziness—Temozolomide—skin cancer	0.000152	0.00169	CcSEcCtD
Rufinamide—Infection—Docetaxel—skin cancer	0.000152	0.00169	CcSEcCtD
Rufinamide—Nausea—Dactinomycin—skin cancer	0.000151	0.00168	CcSEcCtD
Rufinamide—Nervous system disorder—Docetaxel—skin cancer	0.00015	0.00167	CcSEcCtD
Rufinamide—Pruritus—Fluorouracil—skin cancer	0.00015	0.00167	CcSEcCtD
Rufinamide—Thrombocytopenia—Docetaxel—skin cancer	0.00015	0.00167	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—PTCH2—skin cancer	0.000149	0.00289	CbGpPWpGaD
Rufinamide—Skin disorder—Docetaxel—skin cancer	0.000149	0.00165	CcSEcCtD
Rufinamide—Vomiting—Temozolomide—skin cancer	0.000147	0.00163	CcSEcCtD
Rufinamide—SCN5A—Developmental Biology—SCN10A—skin cancer	0.000146	0.00283	CbGpPWpGaD
Rufinamide—Anorexia—Docetaxel—skin cancer	0.000146	0.00162	CcSEcCtD
Rufinamide—Rash—Temozolomide—skin cancer	0.000145	0.00161	CcSEcCtD
Rufinamide—Diarrhoea—Fluorouracil—skin cancer	0.000145	0.00161	CcSEcCtD
Rufinamide—Dermatitis—Temozolomide—skin cancer	0.000145	0.00161	CcSEcCtD
Rufinamide—Headache—Temozolomide—skin cancer	0.000144	0.0016	CcSEcCtD
Rufinamide—Dizziness—Fluorouracil—skin cancer	0.000141	0.00156	CcSEcCtD
Rufinamide—Insomnia—Docetaxel—skin cancer	0.000139	0.00154	CcSEcCtD
Rufinamide—Nausea—Temozolomide—skin cancer	0.000137	0.00152	CcSEcCtD
Rufinamide—Somnolence—Docetaxel—skin cancer	0.000136	0.00151	CcSEcCtD
Rufinamide—Vomiting—Fluorouracil—skin cancer	0.000135	0.0015	CcSEcCtD
Rufinamide—Dyspepsia—Docetaxel—skin cancer	0.000135	0.0015	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—RASA1—skin cancer	0.000135	0.00261	CbGpPWpGaD
Rufinamide—Rash—Fluorouracil—skin cancer	0.000134	0.00149	CcSEcCtD
Rufinamide—Dermatitis—Fluorouracil—skin cancer	0.000134	0.00149	CcSEcCtD
Rufinamide—Decreased appetite—Docetaxel—skin cancer	0.000133	0.00148	CcSEcCtD
Rufinamide—Headache—Fluorouracil—skin cancer	0.000133	0.00148	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000132	0.00147	CcSEcCtD
Rufinamide—Fatigue—Docetaxel—skin cancer	0.000132	0.00147	CcSEcCtD
Rufinamide—GRM5—GPCR downstream signaling—PTGER4—skin cancer	0.000132	0.00256	CbGpPWpGaD
Rufinamide—Constipation—Docetaxel—skin cancer	0.000131	0.00146	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—SHH—skin cancer	0.00013	0.00252	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—RASA1—skin cancer	0.000129	0.0025	CbGpPWpGaD
Rufinamide—Nausea—Fluorouracil—skin cancer	0.000126	0.0014	CcSEcCtD
Rufinamide—SCN4A—Developmental Biology—RASA1—skin cancer	0.000124	0.0024	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—RASA1—skin cancer	0.000124	0.0024	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—SMO—skin cancer	0.000123	0.00239	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—PTCH1—skin cancer	0.000123	0.00239	CbGpPWpGaD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000122	0.00236	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—PTGER4—skin cancer	0.00012	0.00232	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—RASA1—skin cancer	0.00012	0.00231	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—RASA1—skin cancer	0.00012	0.00231	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—RASA1—skin cancer	0.000118	0.00228	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—GLI2—skin cancer	0.000113	0.00219	CbGpPWpGaD
Rufinamide—Hypersensitivity—Docetaxel—skin cancer	0.000113	0.00125	CcSEcCtD
Rufinamide—Asthenia—Docetaxel—skin cancer	0.00011	0.00122	CcSEcCtD
Rufinamide—Pruritus—Docetaxel—skin cancer	0.000108	0.0012	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—MC1R—skin cancer	0.000108	0.00209	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—GLI1—skin cancer	0.000106	0.00206	CbGpPWpGaD
Rufinamide—Diarrhoea—Docetaxel—skin cancer	0.000105	0.00116	CcSEcCtD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000105	0.00203	CbGpPWpGaD
Rufinamide—Dizziness—Docetaxel—skin cancer	0.000101	0.00113	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—SUFU—skin cancer	0.000101	0.00195	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—CDK4—skin cancer	0.0001	0.00194	CbGpPWpGaD
Rufinamide—Vomiting—Docetaxel—skin cancer	9.75e-05	0.00108	CcSEcCtD
Rufinamide—Rash—Docetaxel—skin cancer	9.67e-05	0.00107	CcSEcCtD
Rufinamide—Dermatitis—Docetaxel—skin cancer	9.66e-05	0.00107	CcSEcCtD
Rufinamide—Headache—Docetaxel—skin cancer	9.61e-05	0.00107	CcSEcCtD
Rufinamide—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	9.22e-05	0.00179	CbGpPWpGaD
Rufinamide—Nausea—Docetaxel—skin cancer	9.11e-05	0.00101	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—CDK4—skin cancer	8.94e-05	0.00173	CbGpPWpGaD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	8.91e-05	0.00173	CbGpPWpGaD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.53e-05	0.00165	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—RASA1—skin cancer	8.4e-05	0.00163	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—CDK4—skin cancer	8.18e-05	0.00158	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—NRAS—skin cancer	7.82e-05	0.00151	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—SHH—skin cancer	7.68e-05	0.00149	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—RASA1—skin cancer	7.64e-05	0.00148	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PTCH1—skin cancer	7.28e-05	0.00141	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—SMO—skin cancer	7.28e-05	0.00141	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—PTGER4—skin cancer	7.09e-05	0.00137	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—NRAS—skin cancer	6.97e-05	0.00135	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—KRAS—skin cancer	6.73e-05	0.0013	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—CDK4—skin cancer	6.62e-05	0.00128	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—NRAS—skin cancer	6.37e-05	0.00123	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—CDK4—skin cancer	6.33e-05	0.00123	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—FOXO4—skin cancer	6.26e-05	0.00121	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—CDK4—skin cancer	6.08e-05	0.00118	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—CDK4—skin cancer	6.08e-05	0.00118	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—KRAS—skin cancer	6e-05	0.00116	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—CDK4—skin cancer	5.86e-05	0.00113	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—CDK4—skin cancer	5.86e-05	0.00113	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—HRAS—skin cancer	5.72e-05	0.00111	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—NRAS—skin cancer	5.58e-05	0.00108	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—KRAS—skin cancer	5.49e-05	0.00106	CbGpPWpGaD
Rufinamide—SCN7A—Axon guidance—IL6—skin cancer	5.48e-05	0.00106	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.2e-05	0.00101	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—NRAS—skin cancer	5.16e-05	0.000998	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—HRAS—skin cancer	5.1e-05	0.000987	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—NRAS—skin cancer	4.97e-05	0.000963	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—NRAS—skin cancer	4.93e-05	0.000955	CbGpPWpGaD
Rufinamide—SCN11A—Axon guidance—IL6—skin cancer	4.88e-05	0.000945	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—KRAS—skin cancer	4.8e-05	0.00093	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—NRAS—skin cancer	4.74e-05	0.000917	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—NRAS—skin cancer	4.74e-05	0.000917	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	4.69e-05	0.000907	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—HRAS—skin cancer	4.66e-05	0.000903	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—NRAS—skin cancer	4.57e-05	0.000884	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—NRAS—skin cancer	4.57e-05	0.000884	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—NRAS—skin cancer	4.55e-05	0.000881	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—IL6—skin cancer	4.46e-05	0.000864	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—KRAS—skin cancer	4.44e-05	0.000859	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	4.42e-05	0.000855	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—KRAS—skin cancer	4.28e-05	0.000829	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—KRAS—skin cancer	4.24e-05	0.000822	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TERT—skin cancer	4.18e-05	0.00081	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—CDK4—skin cancer	4.12e-05	0.000798	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—HRAS—skin cancer	4.08e-05	0.00079	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—KRAS—skin cancer	4.08e-05	0.000789	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—KRAS—skin cancer	4.08e-05	0.000789	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—IL6—skin cancer	4.04e-05	0.000781	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—KRAS—skin cancer	3.93e-05	0.000761	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—KRAS—skin cancer	3.93e-05	0.000761	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—KRAS—skin cancer	3.92e-05	0.000758	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—IL6—skin cancer	3.91e-05	0.000756	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—HRAS—skin cancer	3.77e-05	0.00073	CbGpPWpGaD
Rufinamide—ALB—Vitamin B12 Metabolism—IL6—skin cancer	3.72e-05	0.000721	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—NRAS—skin cancer	3.68e-05	0.000712	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—HRAS—skin cancer	3.64e-05	0.000704	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—IL6—skin cancer	3.61e-05	0.000699	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—HRAS—skin cancer	3.61e-05	0.000698	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—NRAS—skin cancer	3.52e-05	0.000682	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—NRAS—skin cancer	3.52e-05	0.000681	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—IL6—skin cancer	3.48e-05	0.000674	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—HRAS—skin cancer	3.47e-05	0.000671	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—HRAS—skin cancer	3.47e-05	0.000671	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—IL6—skin cancer	3.45e-05	0.000668	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—NRAS—skin cancer	3.38e-05	0.000655	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—NRAS—skin cancer	3.38e-05	0.000655	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—HRAS—skin cancer	3.34e-05	0.000647	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—HRAS—skin cancer	3.34e-05	0.000647	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—HRAS—skin cancer	3.33e-05	0.000644	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—IL6—skin cancer	3.32e-05	0.000642	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—IL6—skin cancer	3.32e-05	0.000642	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—BRAF—skin cancer	3.31e-05	0.000641	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—TP53—skin cancer	3.31e-05	0.000641	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—NRAS—skin cancer	3.26e-05	0.000631	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—NRAS—skin cancer	3.26e-05	0.000631	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—NRAS—skin cancer	3.21e-05	0.000622	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—IL6—skin cancer	3.2e-05	0.000619	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—IL6—skin cancer	3.2e-05	0.000619	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—IL6—skin cancer	3.19e-05	0.000617	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—KRAS—skin cancer	3.17e-05	0.000613	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—KRAS—skin cancer	3.03e-05	0.000587	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—IL6—skin cancer	3.03e-05	0.000586	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—KRAS—skin cancer	3.03e-05	0.000586	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—KRAS—skin cancer	2.91e-05	0.000563	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—KRAS—skin cancer	2.91e-05	0.000563	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—KRAS—skin cancer	2.81e-05	0.000543	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—KRAS—skin cancer	2.81e-05	0.000543	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—KRAS—skin cancer	2.76e-05	0.000535	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PLIN2—skin cancer	2.69e-05	0.000522	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—HRAS—skin cancer	2.69e-05	0.000521	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—HRAS—skin cancer	2.58e-05	0.000499	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—IL6—skin cancer	2.58e-05	0.000499	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—HRAS—skin cancer	2.57e-05	0.000498	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—HRAS—skin cancer	2.47e-05	0.000479	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—HRAS—skin cancer	2.47e-05	0.000479	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—IL6—skin cancer	2.47e-05	0.000478	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—IL6—skin cancer	2.46e-05	0.000477	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—IL6—skin cancer	2.41e-05	0.000466	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—HRAS—skin cancer	2.38e-05	0.000462	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—HRAS—skin cancer	2.38e-05	0.000462	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—IL6—skin cancer	2.37e-05	0.000458	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—IL6—skin cancer	2.37e-05	0.000458	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—HRAS—skin cancer	2.35e-05	0.000455	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PLIN2—skin cancer	2.32e-05	0.000448	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—NRAS—skin cancer	2.29e-05	0.000444	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—IL6—skin cancer	2.28e-05	0.000442	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—IL6—skin cancer	2.28e-05	0.000442	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—IL6—skin cancer	2.25e-05	0.000435	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—CSPG4—skin cancer	2.17e-05	0.00042	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—NRAS—skin cancer	2.08e-05	0.000403	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—KRAS—skin cancer	1.97e-05	0.000382	CbGpPWpGaD
Rufinamide—ALB—Metabolism—CSPG4—skin cancer	1.87e-05	0.000361	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—KRAS—skin cancer	1.79e-05	0.000347	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—HRAS—skin cancer	1.68e-05	0.000325	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—IL6—skin cancer	1.6e-05	0.000311	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TP53—skin cancer	1.59e-05	0.000308	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—HRAS—skin cancer	1.52e-05	0.000295	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—ENO2—skin cancer	1.48e-05	0.000286	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—IL6—skin cancer	1.46e-05	0.000282	CbGpPWpGaD
Rufinamide—ALB—Metabolism—ENO2—skin cancer	1.27e-05	0.000246	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PLIN2—skin cancer	1.25e-05	0.000242	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—CSPG4—skin cancer	1.01e-05	0.000195	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.92e-06	0.000192	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—ERCC2—skin cancer	8.57e-06	0.000166	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—NRAS—skin cancer	8.48e-06	0.000164	CbGpPWpGaD
Rufinamide—ALB—Metabolism—ERCC2—skin cancer	7.37e-06	0.000143	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—KRAS—skin cancer	7.3e-06	0.000141	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—ENO2—skin cancer	6.85e-06	0.000133	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—TP53—skin cancer	6.49e-06	0.000126	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—HRAS—skin cancer	6.2e-06	0.00012	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PTGS2—skin cancer	5.14e-06	9.95e-05	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PTGS2—skin cancer	4.42e-06	8.55e-05	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—ERCC2—skin cancer	3.98e-06	7.7e-05	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PTGS2—skin cancer	2.39e-06	4.62e-05	CbGpPWpGaD
